Press Release: AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus 6:30 AM ET 2/11/20 | Dow Jones Related Quotes
8:00 PM ET 2/11/20 Symbol Last % Chg AIM 1.06 0.00% Real time quote.
Ampligen(R) obtained 100% survival rate at clinically achievable human
dosage levels for SARS in animal experiments
Ampligen key to proposed broad-spectrum 'universal' coronavirus vaccine